API

Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals is proud to present its esteemed pharmaceutical compound, Butamirate Citrate, an integral antitussive agent designed to alleviate discomfort in patients suffering from dry, unproductive coughs. Our Butamirate Citrate is an optimal choice for those grappling with upper respiratory tract infections, bronchitis, pneumonia, and even asthma, providing relief from persistent coughing that often accompanies these conditions. Crafted with meticulous attention to quality, our Butamirate Citrate appears as a white to yellowish powder with a slightly waxy texture, assuring ease of incorporation into various dosage forms. Its chemical identity is confirmed through rigorous testing, including the citrate and IR tests, maintaining a high level of purity and performance. The compound exhibits excellent solubility, being freely soluble in water and ethanol (96%), which ensures flexibility in formulation. Adhering to the gold standard of production, Butamirate Citrate holds GMP certification and is characterized by a precise pH range of 3.5 to 4.0. Our commitment to safety and efficacy is evidenced by the thorough analysis that guarantees an assay value between 98.0% - 102.0%, with minimal impurities. Heavy metals content is strictly controlled to ensure patient safety, and residual solvents such as Isopropanol, MTBE, Isopropyl ether, and Toluene are meticulously regulated. Our Butamirate Citrate operates by targeting the cough center in the medulla oblongata to effectively suppress cough reflexes, without reliance on opioids. This action provides a duration of relief for 4-8 hours, allowing for a more comfortable recovery process for the patient. It is suitable for adults and children over the age of 6, with dosage adjustments available to accommodate individual patient responses and tolerability. In conclusion, Refarmed Chemicals' Butamirate Citrate stands as a testament to our dedication to delivering pharmaceutical ingredients of the highest caliber. Our product not only meets the robust demands of the pharmaceutical industry but also provides a critical component for the formulation of efficacious cough suppressants that cater to a wide range of patients.

Products still subject to third-party patent protection might be available solely for R&D purposes.